Mack Roach, III, MD

Title(s)Professor, Radiation Oncology
SchoolSchool of Medicine
Address1600 Divisadero, #H1028
San Francisco CA 94115
Phone415-353-7110
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford UniversityM.D.1979School of Medicine

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    NAPTA: Optimizing clinical trial design & delivery of particle therapy for cancer
    NIH P20CA183640Feb 10, 2015 - Apr 30, 2018
    Role: Principal Investigator
    SFSU/UCSF Comprehensive Cancer Partnership Program
    NIH U56CA096216Jul 1, 2002 - Jun 30, 2010
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Delayed definitive management of localized prostate cancer: what do we know? Prostate Cancer Prostatic Dis. 2024 Aug 11. Mohamad O, Li YR, Feng F, Hong JC, Wong A, El Kouzi Z, Shelan M, Zilli T, Carroll P, Roach M. PMID: 39128937.
      View in: PubMed   Mentions: 1     Fields:    
    2. MRI-Linac-Based Radiotherapy-Promising or Hype? JAMA Oncol. 2024 Aug 01. Roach M, Ling S, Coleman PW. PMID: 39088198.
      View in: PubMed   Mentions:    Fields:    
    3. Pragmatic clinical trials for localized prostate cancer: lessons learned and "three sins". Front Oncol. 2024; 14:1379306. Roach M. PMID: 39119086; PMCID: PMC11306871.
      View in: PubMed   Mentions:
    4. NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 04; 22(3):140-150. Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass DA. PMID: 38626801.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    5. In Memoriam: David A. Larson, MD, PhD, FASTRO (December 17, 1940 - November 4, 2022). Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):322-324. Wallner PE, Knisely JPS, Phillips TL, Roach M, Sahgal A, Steinberg ML. PMID: 38220254.
      View in: PubMed   Mentions:    Fields:    
    6. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 Mar; 10(2):271-278. Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. PMID: 38307806; PMCID: PMC11257781.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. The National Cancer Institute's Cancer Disparities Research Partnership Program: a unique funding model 20 years later. J Natl Cancer Inst. 2023 12 06; 115(12):1465-1474. Coleman CN, Wong R, Petereit DG, Maguire PD, Heron DE, Steinberg M, Bains Y, Vikram B, Angelis P, Livinski AA, Roach M, Govern FS. PMID: 37707545; PMCID: PMC10699796.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Prostate Cancer, Race, and Health Disparity: What We Know. Cancer J. 2023 Nov-Dec 01; 29(6):328-337. Roach M, Coleman PW, Kittles R. PMID: 37963367.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Age 70 +/- 5 Years and Cancer-Specific Outcomes After Treatment of Localized Prostate Cancer: A Systematic Review. Int J Radiat Oncol Biol Phys. 2024 Mar 01; 118(3):672-681. Shaheen H, Salans MA, Mohamad O, Coleman PW, Ahmed S, Roach M. PMID: 37788716.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 10; 21(10):1067-1096. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. PMID: 37856213.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    11. Racism Might Cause Prostate Cancer and Definitely Causes Excess Unemployment, Lost Wages, and Excess Cancer Deaths. J Clin Oncol. 2023 10 01; 41(28):4595-4597. Roach M, Chapman C, Coleman PW. PMID: 37428995.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial. J Clin Oncol. 2023 08 20; 41(24):4035-4044. Michalski JM, Winter KA, Prestidge BR, Sanda MG, Amin M, Bice WS, Gay HA, Ibbott GS, Crook JM, Catton CN, Raben A, Bosch W, Beyer DC, Frank SJ, Papagikos MA, Rosenthal SA, Barthold HJ, Roach M, Moughan J, Sandler HM. PMID: 37315297; PMCID: PMC10461953.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    13. Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. Eur Urol Oncol. 2023 Oct; 6(5):501-507. Sabbagh A, Washington SL, Tilki D, Hong JC, Feng J, Valdes G, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Cowan JE, Cooperberg M, Feng FY, Roach M, Trock BJ, Partin AW, D'Amico AV, Carroll PR, Mohamad O. PMID: 36868922.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    14. Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2023 Feb 22; 6(1):27. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, NRG Prostate Cancer AI Consortium, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. PMID: 36813827; PMCID: PMC9947124.
      View in: PubMed   Mentions:
    15. AUA/ASTRO 2022 Guidelines: "Scrutinized". Pract Radiat Oncol. 2023 May-Jun; 13(3):172-174. Roach Iii M, Coleman PW, Sabol RA. PMID: 36882350.
      View in: PubMed   Mentions:    Fields:    
    16. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. 2024 Apr; 85(4):373-381. Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, Mishra MV, Roach M, Parliament MB, Choi KN, Pisansky TM, Husain SM, Malone SC, Horwitz EM, Feng F. PMID: 36710205; PMCID: PMC10372191.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Re: Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities. JCO Oncol Pract. 2023 05; 19(5):219-220. Roach M, Coleman PW. PMID: 36657093.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul 15; 116(4):770-778. Lukka HR, Deshmukh S, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Feng FY, Pugh SL, Sandler HM, Kachnic LA. PMID: 36592721; PMCID: PMC10619484.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    19. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. Int J Radiat Oncol Biol Phys. 2023 07 01; 116(3):521-529. Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, Tran P, Feng FY. PMID: 36596347; PMCID: PMC10281690.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    20. Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. Cancer. 2023 03 01; 129(5):685-696. McDonald AM, DeMora L, Yang ES, Hoyle JM, Lenzie A, Williams GR, Michalski JM, Yee D, Bahary JP, Den RB, Roach M, Dess R, Mishra MV, Valicenti RK, Lau HY, Marcrom SR, Souhami L, Mendez LC, Chen Y, Doncals DE, Pugh SL, Feng FY, Sandler HM. PMID: 36579470; PMCID: PMC10231027.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022 12; 20(12):1288-1298. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. PMID: 36509074.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    22. Editorial Comment. J Urol. 2022 12; 208(6):1238-1239. Sabol RA, Roach M. PMID: 36349917.
      View in: PubMed   Mentions:    Fields:    
    23. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. J Clin Oncol. 2023 02 01; 41(4):881-892. Ma TM, Sun Y, Malone S, Roach M, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, Carrier N, Souhami L, Zapatero A, Guerrero A, Alvarez A, Gonzalez San-Segundo C, Maldonado X, Romero T, Steinberg ML, Valle LF, Rettig MB, Nickols NG, Shoag JE, Reiter RE, Zaorsky NG, Jia AY, Garcia JA, Spratt DE, Kishan AU, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. PMID: 36269935; PMCID: PMC9902004.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    24. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). Eur Urol. 2022 11; 82(5):487-498. Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, Souhami L, Carrier N, Incrocci L, Heemsbergen W, Pos FJ, Sydes MR, Dearnaley DP, Tree AC, Syndikus I, Hall E, Cruickshank C, Malone S, Roy S, Sun Y, Zaorsky NG, Nickols NG, Reiter RE, Rettig MB, Steinberg ML, Reddy VK, Xiang M, Romero T, Spratt DE, Kishan AU, Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators. PMID: 35934601.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    25. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2022 Jun 08; 5(1):71. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, NRG Prostate Cancer AI Consortium, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. PMID: 35676445; PMCID: PMC9177850.
      View in: PubMed   Mentions: 29  
    26. Moving Beyond Race-Based Medicine. Ann Intern Med. 2022 03; 175(3):W20. Roach M. PMID: 35286821.
      View in: PubMed   Mentions:    Fields:    
    27. Race, Biology, Disparities, and Prostate Cancer. Eur Urol. 2022 05; 81(5):463-465. Vickers AJ, Elfiky A, Freeman VL, Roach M. PMID: 35216858.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. Commentary: Race, COVID-19 and Nursing Homes. J Infect Dis. 2022 02 15; 225(4):555-556. Roach M, Hiatt RA, Black S. PMID: 34618903; PMCID: PMC8754694.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    29. Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. JAMA Netw Open. 2021 12 01; 4(12):e2139769. Ma TM, Romero T, Nickols NG, Rettig MB, Garraway IP, Roach M, Michalski JM, Pisansky TM, Lee WR, Jones CU, Rosenthal SA, Wang C, Hartman H, Nguyen PL, Feng FY, Boutros PC, Saigal C, Chamie K, Jackson WC, Morgan TM, Mehra R, Salami SS, Vince R, Schaeffer EM, Mahal BA, Dess RT, Steinberg ML, Elashoff D, Sandler HM, Spratt DE, Kishan AU. PMID: 34964855; PMCID: PMC8717118.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer. 2022 01; 160:24-60. Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, Gillessen S, APCCC 2019 expert panel. PMID: 34844839.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    31. Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526). Int J Radiat Oncol Biol Phys. 2022 04 01; 112(5):1115-1122. Crook J, Rodgers JP, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Murtha AD, Vigneault E, Helou J, Michalski JM, Roach M, Beyer D, Jani AB, Horwitz EM, Raben A, Pugh S, Sandler H. PMID: 34740768; PMCID: PMC8923978.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    32. Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines. 2021 Sep 17; 9(9). Henríquez I, Roach M, Morgan TM, Bossi A, Gómez JA, Abuchaibe O, Couñago F. PMID: 34572433; PMCID: PMC8468423.
      View in: PubMed   Mentions: 27  
    33. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):294-303. Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. PMID: 34481017; PMCID: PMC8748315.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    34. Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation. Pract Radiat Oncol. 2021 Nov-Dec; 11(6):515-526. Wu SY, Wong AC, Shinohara K, Roach M, Cunha JAM, Valdes G, Hsu IC. PMID: 34077809.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    35. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021 Mar 09; 16(1):50. Rogowski P, Roach M, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R, Buchner A, Stief C, Belka C, Li M. PMID: 33750437; PMCID: PMC7941976.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    36. Radiation Delay Is Okay, but Where Is the Evidence? JAMA Oncol. 2021 03 01; 7(3):463-464. Mohamad O, Roach M. PMID: 33443566.
      View in: PubMed   Mentions:    Fields:    
    37. Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncol. 2021 01; 22(1):11-13. Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M, Lawton CAF. PMID: 33387489; PMCID: PMC8882263.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    38. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis. Int J Radiat Oncol Biol Phys. 2021 06 01; 110(2):429-437. Chen WC, Li Y, Lazar A, Altun A, Descovich M, Nano T, Ziemer B, Sudhyadhom A, Cunha A, Thomas H, Gottschalk A, Hsu IC, Roach M. PMID: 33385496.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    39. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. J Clin Oncol. 2021 01 10; 39(2):136-144. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CAF. PMID: 33275486; PMCID: PMC8189640.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    40. Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys. 2021 Jul 01; 110(3):700-707. Hsu IC, Rodgers JP, Shinohara K, Purdy J, Michalski J, Roach M, Vigneault E, Ivker RA, Pryzant RM, Kuettel M, Taussky D, Gustafson GS, Raben A, Sandler HM. PMID: 33186617; PMCID: PMC8107184.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    41. Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review. JAMA Oncol. 2020 Nov 01; 6(11):1793-1800. Sachdev S, Carroll P, Sandler H, Nguyen PL, Wafford E, Auffenberg G, Schaeffer E, Roach M, Evans CP, Hussain M. PMID: 32852528.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    42. Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):337. Mohamad O, Roach M. PMID: 32890501; PMCID: PMC7462932.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    43. Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer. Invest New Drugs. 2021 04; 39(2):499-508. Gartrell BA, Roach M, Retter A, Sokol GH, Del Priore G, Scher HI. PMID: 32924093; PMCID: PMC7960617.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    44. Editorial Comment. J Urol. 2020 11; 204(5):954. Roach M. PMID: 32909883.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Ther Adv Med Oncol. 2020; 12:1758835920936084. Han HJ, Li YR, Roach M, Aggarwal R. PMID: 32922519; PMCID: PMC7450451.
      View in: PubMed   Mentions: 18  
    46. The Roach Equation: Value of Old Clinical Tools in the Era of New Molecular Imaging. J Nucl Med. 2020 09; 61(9):1292-1293. Li YR, Roach M. PMID: 32444373; PMCID: PMC7456176.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020 09 10; 38(26):3024-3031. Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M, Spratt DE. PMID: 32396488; PMCID: PMC8265327.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    48. Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 07 15; 107(4):766-778. Griffin RJ, Ahmed MM, Amendola B, Belyakov O, Bentzen SM, Butterworth KT, Chang S, Coleman CN, Djonov V, Formenti SC, Glatstein E, Guha C, Kalnicki S, Le QT, Loo BW, Mahadevan A, Massaccesi M, Maxim PG, Mohiuddin M, Mohiuddin M, Mayr NA, Obcemea C, Petersson K, Regine W, Roach M, Romanelli P, Simone CB, Snider JW, Spitz DR, Vikram B, Vozenin MC, Abdel-Wahab M, Welsh J, Wu X, Limoli CL. PMID: 32298811.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    49. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. PMID: 32001144.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    50. Re: Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. Eur Urol. 2020 04; 77(4):558-559. Li YR, Roach M. PMID: 31839490.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119. Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA. PMID: 31502940; PMCID: PMC8274949.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    52. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. PMID: 31120534; PMCID: PMC6547116.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCTClinical Trials
    53. Stampede to Cure. Int J Radiat Oncol Biol Phys. 2019 06 01; 104(2):264. Li YR, Roach M. PMID: 31047624.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 05 01; 17(5):479-505. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. PMID: 31085757.
      View in: PubMed   Mentions: 517     Fields:    Translation:Humans
    55. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2019 08 01; 104(5):1057-1065. Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM. PMID: 30959123; PMCID: PMC6646073.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    56. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neurooncol Pract. 2019 Dec; 6(6):473-478. Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP. PMID: 31832217; PMCID: PMC6899045.
      View in: PubMed   Mentions: 5  
    57. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. Eur Urol Oncol. 2019 05; 2(3):294-301. Ventimiglia E, Seisen T, Abdollah F, Briganti A, Fonteyne V, James N, Roach M, Thalmann GN, Touijer K, Chen RC, Cheng L. PMID: 31200844.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    58. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. Eur Urol Oncol. 2019 11; 2(6):685-690. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, Feng FY. PMID: 31411984.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    59. Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus? Eur Urol. 2019 04; 75(4):556-557. Sooriakumaran P, Pavan N, Wiklund PN, Roach M. PMID: 30639140.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    60. Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology. 2019 03; 125:154-162. Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA. PMID: 30580002.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    61. Clinical trials involving carbon-ion radiation therapy and the path forward. Cancer. 2018 12 01; 124(23):4467-4476. Lazar AA, Schulte R, Faddegon B, Blakely EA, Roach M. PMID: 30307603; PMCID: PMC6540799.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    62. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1504-1515. Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. PMID: 30316827; PMCID: PMC6540797.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCTClinical Trials
    63. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys. 2019 02 01; 103(2):335-343. Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H. PMID: 30312717; PMCID: PMC6368223.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    64. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):287-295. Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA. PMID: 29913254; PMCID: PMC6248906.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    65. Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities. Adv Radiat Oncol. 2018 Jul-Sep; 3(3):405-411. Xiao C, Moughan J, Movsas B, Konski AA, Hanks GE, Cox JD, Roach M, Zeitzer KL, Lawton CA, Peters CA, Rosenthal SA, Hsu IJ, Horwitz EM, Mishra MV, Michalski JM, Parliament MB, D'Souza DP, Pugh SL, Bruner DW. PMID: 30202809; PMCID: PMC6128023.
      View in: PubMed   Mentions: 2  
    66. Optimizing Imperfect Patient Management Recommendations Post-prostatectomy. Eur Urol Oncol. 2018 05; 1(1):19-20. Roach M, Lazar AA. PMID: 31100223.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    67. Re: Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation. Eur Urol. 2018 04; 73(4):638-639. Roach M. PMID: 29275834.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now? Pract Radiat Oncol. 2018 May - Jun; 8(3):185-202. Gonzalez-Motta A, Roach M. PMID: 29339046.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    69. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. PMID: 28655541.
      View in: PubMed   Mentions: 189     Fields:    Translation:Humans
    70. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):296-303. Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ, Sandler HM. PMID: 28463149; PMCID: PMC5603177.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    71. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. 2017 11; 72(5):689-709. Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M. PMID: 28189428.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    72. Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e109-e116. Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M, Seymour ZA. PMID: 28274401.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    73. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. Technol Cancer Res Treat. 2017 04; 16(2):178-187. Wahl M, Descovich M, Shugard E, Pinnaduwage D, Sudhyadhom A, Chang A, Roach M, Gottschalk A, Chen J. PMID: 27199276; PMCID: PMC5616028.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    74. Prostate cancer: Combining endocrine treatment and radiotherapy: a bright future. Nat Rev Urol. 2016 07; 13(7):373-4. Roach M. PMID: 27245503.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    75. Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer. J Urol. 2016 08; 196(2):308-9. Roach M. PMID: 27164515.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    76. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2016 Apr; 39(2):167-72. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. PMID: 24441584.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation. Technol Cancer Res Treat. 2017 06; 16(3):267-275. Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M, Gottschalk AR. PMID: 27037301; PMCID: PMC5616040.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Words of Wisdom. Re: Genomic Classifier Identifies Men with Adverse Pathology After Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy. Eur Urol. 2016 Mar; 69(3):539-40. Chan J, Roach M. PMID: 26867726.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    79. Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30: Radical Prostatectomy Versus Radiation for Clinically Localized Prostate Cancer: Two Systematic Reviews and a Randomized Controlled Trial. Eur Urol. 2016 07; 70(1):e13-e14. Lazar AA, Lizarraga TLC, Roach M. PMID: 26935558.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    80. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016 Jan 21; 11:8. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. PMID: 26792201; PMCID: PMC4721063.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    81. New Clinical and Research Programs in Particle Beam Radiation Therapy: The University of California San Francisco Perspective. Int J Part Ther. 2016; 2(3):471-473. Roach M, Schulte R, Mishra K, Faddegon B, Barani I, Lazar A, Blakely EA. PMID: 27099866; PMCID: PMC4834449.
      View in: PubMed   Mentions: 4  
    82. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 01; 14(1):19-30. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. PMID: 26733552.
      View in: PubMed   Mentions: 265     Fields:    Translation:Humans
    83. Sentinel lymph node imaging guided IMRT for prostate cancer: Individualized pelvic radiation therapy versus RTOG guidelines. Adv Radiat Oncol. 2016 Jan-Mar; 1(1):51-58. Chen CP, Johnson J, Seo Y, Weinberg VK, Shinohara K, Hsu IJ, Roach M. PMID: 28799574; PMCID: PMC5506713.
      View in: PubMed   Mentions:
    84. Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence? Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):1064-70. Roach M, Ceron Lizarraga TL, Lazar AA. PMID: 26581143.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    85. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015 Nov; 45(Pt B):443-448. Kaplan CP, Nápoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, Roach M, Small EJ. PMID: 26435199.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    86. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Nov-Dec; 14(6):795-800. Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M, Hsu IC. PMID: 26198421.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    87. Reporting of results in DART01/05 GICOR. Lancet Oncol. 2015 Jun; 16(6):e258. Pisansky TM, Suman VJ, Roach M, Sandler HM. PMID: 26065604.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    88. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20. Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll PR. PMID: 25600860.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    89. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll PR. PMID: 25983194.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    90. Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine. Eur Urol. 2015 Nov; 68(5):775-6. Bossi A, Wiegel T, Roach M. PMID: 25976403.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    91. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-e472. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. PMID: 25795252.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    92. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):185-8. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M. PMID: 25533416.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    93. Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15; 121(6):844-52. Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM. PMID: 25410885; PMCID: PMC4657945.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    94. Natural History after Biochemical Failure Following Dose-escalated External Beam Radiation: An Opportunity to Improve Outcomes? Eur Urol. 2015 Jun; 67(6):1017-1018. Roach M. PMID: 25457015.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    95. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015 May; 67(5):852-63. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M, Briganti A. PMID: 25240974.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    96. Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. PMID: 25097554; PMCID: PMC4105644.
      View in: PubMed   Mentions: 2  
    97. Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: single-institution prospective study at University of California, San Francisco. Pract Radiat Oncol. 2015 Jan-Feb; 5(1):e45-51. Chen CP, Braunstein S, Mourad M, Hsu IC, Haas-Kogan D, Roach M, Fogh SE. PMID: 25413428.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    98. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014 Jun; 11(6):308-23. Chang AJ, Autio KA, Roach M, Scher HI. PMID: 24840073; PMCID: PMC4508854.
      View in: PubMed   Mentions: 218     Fields:    Translation:Humans
    99. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M, National Comprehensive Cancer Network. PMID: 24812137.
      View in: PubMed   Mentions: 130     Fields:    Translation:Humans
    100. Radium-223 vs EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park). 2014 Apr; 28(4):297-8. Roach M. PMID: 24839801.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    101. Radical prostatectomy v radiation: only a randomised trial can provide the answer. BMJ. 2014 Mar 25; 348:g2266. Roach M. PMID: 24668796.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    102. Prostate cancer: impact of national guidelines on brachytherapy monotherapy. Nat Rev Urol. 2014 Apr; 11(4):195-6. Johnson J, Roach M. PMID: 24619374.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    103. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. PMID: 24594774; PMCID: PMC3940667.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    104. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer. 2014 Jun 01; 120(11):1620-9. Roach M. PMID: 24591080.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    105. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014 Feb 02; 9:42. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. PMID: 24484652; PMCID: PMC3923240.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    106. Offline multiple adaptive planning strategy for concurrent irradiation of the prostate and pelvic lymph nodes. Med Phys. 2014 Feb; 41(2):021704. Qi P, Pouliot J, Roach M, Xia P. PMID: 24506595.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    107. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014 Feb; 110(2):303-8. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M, Carroll PR, Coakley FV. PMID: 24444524; PMCID: PMC3969841.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    108. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013 Dec 01; 11(12):1471-9. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M, National comprehensive cancer network. PMID: 24335682.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    109. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50. Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J. PMID: 24231238; PMCID: PMC4081029.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys. 2013 Sep 06; 14(5):162-72. Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M, Gottschalk AR. PMID: 24036869; PMCID: PMC5714582.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    111. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1034-43. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ. PMID: 23972524.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    112. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):822-8. Valicenti RK, Thompson I, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, Roach M, Faraday MM, American Society for Radiation Oncology/American Urological Association. PMID: 23845839.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    113. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug; 190(2):441-9. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS, Faraday MM. PMID: 23707439.
      View in: PubMed   Mentions: 138     Fields:    Translation:Humans
    114. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol. 2013 Apr 25; 8:100. Pan L, Baek S, Edmonds PR, Roach M, Wolkov H, Shah S, Pollack A, Hammond ME, Dicker AP. PMID: 23618468; PMCID: PMC3653757.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    115. Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):600-5. Kaidar-Person O, Roach M, Créhange G. PMID: 23523182.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    116. Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Jun 01; 119(11):1999-2004. Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. PMID: 23504930; PMCID: PMC3663874.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    117. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):324-9. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. PMID: 23474112.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansPHPublic Health
    118. Cautious optimism for extreme dose escalation in prostate cancer. Eur Urol. 2013 Dec; 64(6):939-40. Chang AJ, Roach M. PMID: 23506832.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat. 2013 Jun; 12(3):199-206. Pejavar S, Yom SS, Hwang A, Speight J, Gottschalk A, Hsu IC, Roach M, Xia P. PMID: 23289478.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    120. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):221-9. Roach M, Thomas K. PMID: 23271777; PMCID: PMC3540886.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    121. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Sep; 10(9):1081-7. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. PMID: 22956807.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    122. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e363-70. Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD. PMID: 22633552; PMCID: PMC3361689.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    123. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev. 2012 Dec; 38(8):956-67. Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M. PMID: 22703831; PMCID: PMC3739983.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    124. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):370-7. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M. PMID: 22672747.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansPHPublic Health
    125. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1186-91. Meijer HJ, Debats OA, Roach M, Span PN, Witjes JA, Kaanders JH, van Lin EN, Barentsz JO. PMID: 22520482.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    126. Radium-223: down to the bone, and less is more. Oncology (Williston Park). 2012 Apr; 26(4):342, 344. Chang AJ, Roach M. PMID: 22655526.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    127. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012 Jun; 61(6):1096-106. Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ. PMID: 22386839.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    128. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012 Jul; 110(2):225. Roach M. PMID: 22734476.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    129. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):e787-93. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carroll PR, Coakley FV. PMID: 22331003; PMCID: PMC3285390.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    130. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb; 109 Suppl 1:22-9. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. PMID: 22239226.
      View in: PubMed   Mentions: 152     Fields:    Translation:Humans
    131. Irradiation of the prostate and pelvic lymph nodes with an adaptive algorithm. Med Phys. 2012 Feb; 39(2):1119-24. Hwang AB, Chen J, Nguyen TB, Gottschalk AG, Roach MR, Pouliot J. PMID: 22320822.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    132. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):e657-62. Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M, Cheung P, Sahgal A. PMID: 22245189.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    133. Editorial comment. Urology. 2011 Dec; 78(6):1367-8. Roach M. PMID: 22137705.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    134. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21; 56(24):7767-75. Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L. PMID: 22107791.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    135. Indications and practice with androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S478-81. Moul JW, Kibel AS, Roach M, Dreicer R. PMID: 22054918.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    136. Traditional approaches to androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S485-93. Moul JW, Evans CP, Gomella LG, Roach M, Dreicer R. PMID: 22054920.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    137. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol. 2012 Mar; 61(3):443-51. Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M, van Poppel H, Zietman A. PMID: 22036777.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    138. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy. 2012 Sep-Oct; 11(5):348-53. Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M, Hsu IC. PMID: 21937284.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    139. Validation of a Predictive Model for Survival in Patients With Advanced Cancer: Secondary Analysis of RTOG 9714. World J Oncol. 2011 08; 2(4):181-190. Chow E, James JL, Hartsell W, Scarantino CW, Ivker R, Roach M, Suh JH, Demas W, Konski A, Bruner DW. PMID: 29147245; PMCID: PMC5649656.
      View in: PubMed   Mentions: 8  
    140. Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment. Urol Clin North Am. 2011 Aug; 38(3):303-12. Moyad MA, Roach M. PMID: 21798392.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    141. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys. 2011 May 01; 80(1):6-16. Morikawa LK, Roach M. PMID: 21481721.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    142. Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions. J Surg Oncol. 2011 May 01; 103(6):587-601. Roach M, Alberini JL, Pecking AP, Testori A, Verrecchia F, Soteldo J, Ganswindt U, Joyal JL, Babich JW, Witte RS, Unger E, Gottlieb R. PMID: 21480253.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    143. Endorectal MRI after radiation therapy: questioning the sextant analysis. J Magn Reson Imaging. 2011 May; 33(5):1086-90. Kumbhani SR, Coakley FV, McCulloch CE, Wang ZJ, Kurhanewicz J, Roach M, Westphalen AC. PMID: 21509865; PMCID: PMC3081102.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    144. Benefits and pitfalls of prostate cancer screening: "no proof of benefit" does not equal "proof of no benefit". Oncology (Williston Park). 2011 May; 25(6):466, 468. Chen CP, Staggers FE, Roach M. PMID: 21717899.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    145. Predicting the risk of pelvic node involvement in men with prostate cancer in the contemporary era: change you can believe?: in regard to Yu, et al. (Int J Radiat Oncol Biol Phys in press). Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1598; author reply 1598-9. Hayes M, Roach M. PMID: 21414516.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    146. Editorial comment. Urology. 2011 Apr; 77(4):991-2; author reply 992-3. Roach M. PMID: 21477731.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    147. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1293-301. Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. PMID: 21458924; PMCID: PMC4675045.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    148. Successful radiation treatment of anaplastic thyroid carcinoma metastatic to the right cardiac atrium and ventricle in a pacemaker-dependent patient. Radiat Oncol. 2011 Feb 14; 6:16. Dasgupta T, Barani IJ, Roach M. PMID: 21320341; PMCID: PMC3049119.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    149. Editorial comment. BJU Int. 2011 Jan; 107(2):232-3. Roach M. PMID: 21208366.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    150. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):228-34. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR. PMID: 21183287.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    151. High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):222-7. Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M, Shinohara K, Hsu IC. PMID: 21163586.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    152. Primary focal unilateral nerve-sparing cryoablation for very early prostate cancer: is it enough or too much, or do we know? Cancer J. 2010 Sep-Oct; 16(5):542-3. Roach M. PMID: 20890153.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    153. Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes. Med Phys. 2010 Sep; 37(9):5006-13. Xia P, Qi P, Hwang A, Kinsey E, Pouliot J, Roach M. PMID: 20964220.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    154. Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):445-52. Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. PMID: 20615632; PMCID: PMC2952349.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    155. Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol. 2010 Oct 01; 28(28):e518-9; author reply e521-e522. Hamstra DA, Michalski JM, Roach M, Sandler HM. PMID: 20660824.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    156. Who, when, where, and how: salvage prostate cancer with radiotherapy. Oncology (Williston Park). 2010 Jul; 24(8):702, 704. Chien CP, Roach M. PMID: 20718249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    157. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology. 2010 Aug; 256(2):485-92. Westphalen AC, Coakley FV, Roach M, McCulloch CE, Kurhanewicz J. PMID: 20551184; PMCID: PMC2909433.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    158. Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1314-22. Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. PMID: 20378270; PMCID: PMC2920356.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    159. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3 Suppl):S130-4. Roach M, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. PMID: 20171507; PMCID: PMC4786051.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansPHPublic Health
    160. Prostate cancer: worse sexual function after cryoablation--a case for EBRT? Nat Rev Urol. 2010 Mar; 7(3):122-4. Roach M. PMID: 20220752.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    161. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):58-63. Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M, Ma L. PMID: 20133073.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    162. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):162-200. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. PMID: 20141676.
      View in: PubMed   Mentions: 359     Fields:    Translation:Humans
    163. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys. 2010 Jan 01; 76(1):14-22. Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD. PMID: 19577865; PMCID: PMC2795116.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    164. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys. 2010 Jan 01; 76(1):36-42. Jabbari S, Weinberg VK, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M. PMID: 19409729.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    165. Editorial comment. J Urol. 2010 Feb; 183(2):551. Roach M. PMID: 20006855.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    166. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era: change you can believe in, or back to the future? (In regard to Nguyen PL, et al. (Int J Radiat Oncol Biol Phys 2009). Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):316; author reply 316. Roach M. PMID: 19695446.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    167. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol. 2009 Aug; 32(4):423-8. Konski A, James J, Hartsell W, Leibenhaut MH, Janjan N, Curran W, Roach M, Watkins-Bruner D. PMID: 19546803; PMCID: PMC2941643.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    168. Functional interference clusters in cancer patients with bone metastases: a secondary analysis of RTOG 9714. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1507-11. Chow E, James J, Barsevick A, Hartsell W, Ratcliffe S, Scarantino C, Ivker R, Roach M, Suh J, Petersen I, Konski A, Demas W, Bruner D. PMID: 19632065; PMCID: PMC2846210.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    169. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer. 2009 Jul 01; 115(13 Suppl):3112-20. Roach M, Waldman F, Pollack A. PMID: 19544539; PMCID: PMC2760302.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    170. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1061-5. Potters L, Roach M, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW. PMID: 19540064.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    171. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy. 2009 Oct-Dec; 8(4):339-44. Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, Roach M, Shinohara K. PMID: 19428310.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    172. ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):667-72. Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. PMID: 19386445.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    173. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int. 2009 Sep; 104(5):600-4. Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, Shinohara K. PMID: 19245439.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    174. Predicting pathologic stage, nomograms, and clinical judgment: don't miss the forest for the trees! Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):325-6. Roach M. PMID: 19147013.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    175. Clinical decisions. Management of prostate cancer. N Engl J Med. 2008 Dec 11; 359(24):2605-9. Schröder FH, Roach M, Scardino P. PMID: 19073981.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    176. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):377-82. Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M, Pisansky TM, Seider M. PMID: 18947941; PMCID: PMC2905162.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    177. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):247-54. Sahgal A, Jabbari S, Chen J, Pickett B, Roach M, Weinberg V, Hsu IC, Pouliot J. PMID: 18722275.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    178. Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):665-71. Joseph T, McKenna DA, Westphalen AC, Coakley FV, Zhao S, Lu Y, Hsu IC, Roach M, Kurhanewicz J. PMID: 18760545; PMCID: PMC2737354.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    179. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol. 2008 Aug 01; 26(22):3816-7; author reply 3817-8. Roach M. PMID: 18669477.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    180. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Jul 10; 359(2):200; author reply 201-2. Yu JS, Roach M. PMID: 18614788.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    181. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):341-6. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG. PMID: 18597953.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    182. "Short- and long-term mortality with localized prostate cancer": errors and omissions? Arch Intern Med. 2008 Jun 23; 168(12):1351; author reply 1353. Roach M. PMID: 18574095.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    183. Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14. J Palliat Med. 2008 Jun; 11(5):723-8. Hartsell WF, Desilvio M, Bruner DW, Scarantino C, Ivker R, Roach M, Suh J, Demas WF, Movsas B, Petersen IA, Konski AA. PMID: 18588404.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    184. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):53-60. Chung HT, Xia P, Chan LW, Park-Somers E, Roach M. PMID: 18501530.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansPHPublic Health
    185. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):69-77. Chan LW, Xia P, Gottschalk AR, Akazawa M, Scala M, Pickett B, Hsu IC, Speight J, Roach M. PMID: 18342454.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    186. Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. Urology. 2008 Nov; 72(5):1125-9. Taussky D, Bae K, Bahary JP, Roach M, Lawton CA, Shipley WU, Sandler HM. PMID: 18314175.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    187. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):671-7. D'Ambrosio DJ, Pollack A, Harris EE, Price RA, Verhey LJ, Roach M, Demanes DJ, Steinberg ML, Potters L, Wallner PE, Konski A. PMID: 18262085.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    188. Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience. Radiology. 2008 Apr; 247(1):141-6. McKenna DA, Coakley FV, Westphalen AC, Zhao S, Lu Y, Webb EM, Pickett B, Roach M, Kurhanewicz J. PMID: 18258811; PMCID: PMC3694427.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    189. Technique for implantation of fiducial markers in the prostate. Urology. 2008 Feb; 71(2):196-200. Shinohara K, Roach M. PMID: 18308082.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    190. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 01; 26(4):585-91. Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. PMID: 18172188.
      View in: PubMed   Mentions: 200     Fields:    Translation:HumansCTClinical Trials
    191. Are lateral electronic portal images adequate for accurate on-line daily targeting of the prostate? Results of a prospective study. Med Dosim. 2008; 33(1):22-9. Lometti MW, Thurston D, Aubin M, Bock A, Verhey L, Lockhart JM, Bland R, Pouliot J, Roach M. PMID: 18262119.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    192. An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes. Med Phys. 2007 Dec; 34(12):4750-6. Ludlum E, Mu G, Weinberg V, Roach M, Verhey LJ, Xia P. PMID: 18196802.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    193. Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application. Nat Clin Pract Urol. 2007 Dec; 4(12):658-70. Sahgal A, Roach M. PMID: 18059346.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    194. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both? Strahlenther Onkol. 2007 Dec; 183 Spec No 2:26-8. Roach M. PMID: 18167004.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    195. Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk? J Clin Oncol. 2007 Nov 20; 25(33):5325-6; author reply 5326. Roach M. PMID: 18024880.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    196. Editorial comment on: high provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol. 2008 Jul; 54(1):105-6. Roach M. PMID: 17997012.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    197. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1472-7. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG. PMID: 17689026.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    198. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug; 5(7):650-83. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC, National Comprehensive Cancer Nerwork. PMID: 17692170.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    199. Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia. 2007 Jun; 9(6):455-63. Zapotoczna A, Sasso G, Simpson J, Roach M. PMID: 17603627; PMCID: PMC1899254.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    200. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):646-55. Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR. PMID: 17531401; PMCID: PMC2917177.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    201. Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1199-206. Litzenberg DW, Willoughby TR, Balter JM, Sandler HM, Wei J, Kupelian PA, Cunningham AA, Bock A, Aubin M, Roach M, Shinohara K, Pouliot J. PMID: 17513060.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    202. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2007 Sep 01; 69(1):79-87. Roach M, De Silvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, Fisher B, Hanks G, Shipley WU, Pollack A, Sandler H, Watkins-Bruner D. PMID: 17498886.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    203. Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol. 2007 Mar 10; 25(8):987-95. Speight JL, Roach M. PMID: 17350948.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    204. Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opin Pharmacother. 2007 Feb; 8(2):257-64. Roach M, Izaguirre A. PMID: 17257094.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    205. State-of-the-art radiotherapy in the management of clinically localized prostate carcinoma. Future Oncol. 2007 Feb; 3(1):103-11. Bermudez RS, Izaguirre A, Roach M. PMID: 17280507.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    206. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):610-9. Schiffner DC, Gottschalk AR, Lometti M, Aubin M, Pouliot J, Speight J, Hsu IC, Shinohara K, Roach M. PMID: 17236978.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    207. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer. 2007 Jan 15; 109(2):213-20. Roach M, Weinberg V, Sandler H, Thompson I. PMID: 17167758.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    208. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. 2007 Jan-Mar; 6(1):2-8. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. PMID: 17284379.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    209. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007 Mar 15; 67(4):1106-12. Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M, Hsu IC. PMID: 17197119.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    210. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol. 2006 Dec; 176(6 Pt 2):S16-20. Roach M, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW. PMID: 17084158.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    211. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):654-62. Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M. PMID: 17011444.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    212. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):647-53. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR, Shipley WU. PMID: 17011443.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    213. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):965-74. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. PMID: 16798415.
      View in: PubMed   Mentions: 894     Fields:    Translation:Humans
    214. Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Jun 01; 65(2):528-34. Willoughby TR, Kupelian PA, Pouliot J, Shinohara K, Aubin M, Roach M, Skrumeda LL, Balter JM, Litzenberg DW, Hadley SW, Wei JT, Sandler HM. PMID: 16690435.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    215. Radiotherapy in the management of common genitourinary malignancies. Hematol Oncol Clin North Am. 2006 Apr; 20(2):321-46. Speight JL, Roach M. PMID: 16730297.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    216. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys. 2006 May 01; 65(1):65-72. Pickett B, Kurhanewicz J, Pouliot J, Weinberg V, Shinohara K, Coakley F, Roach M. PMID: 16517094.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    217. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol. 2006 Feb; 29(1):14-20. Abdel-Wahab M, Berkey BA, Krishan A, O'Brien T, Hammond E, Roach M, Lawton C, Pilepich M, Markoe A, Pollack A. PMID: 16462497.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    218. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1162-7. Shipley WU, Desilvio M, Pilepich MV, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA. PMID: 16427211.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    219. New techniques and management options for localized prostate cancer. Rev Urol. 2006; 8 Suppl 2:S22-9. Speight JL, Roach M. PMID: 17021638; PMCID: PMC1578718.
      View in: PubMed   Mentions: 3  
    220. Megavoltage cone-beam CT: system description and clinical applications. Med Dosim. 2006; 31(1):51-61. Morin O, Gillis A, Chen J, Aubin M, Bucci MK, Roach M, Pouliot J. PMID: 16551529.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    221. Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. Cancer. 2005 Dec 01; 104(11):2310-22. Soloway M, Roach M. PMID: 16222694.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    222. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol. 2005 Nov 10; 23(32):8176-85. Speight JL, Roach M. PMID: 16278470.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    223. Radiotherapy plus adjuvant goserelin improves survival in men with poor prognosis prostate cancer. Cancer Treat Rev. 2005 Nov; 31(7):582-6. Roach M. PMID: 16256275.
      View in: PubMed   Mentions: 1     Fields:    
    224. Commentary on increased risk of biochemical and local failure in patients with a distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):949-50. Roach M. PMID: 15989992.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    225. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005 Jul 01; 62(3):706-13. Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD. PMID: 15936549.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    226. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005 Jun 01; 97(11):798-804. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. PMID: 15928300.
      View in: PubMed   Mentions: 228     Fields:    Translation:HumansCTClinical Trials
    227. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. 2005 May 01; 62(1):3-19. Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M, Gore EM, Tepper JE. PMID: 15850897.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    228. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin. 2005 Mar-Apr; 55(2):117-34. Bucci MK, Bevan A, Roach M. PMID: 15761080.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    229. Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):552-60. Pouliot J, Bani-Hashemi A, Chen J, Svatos M, Ghelmansarai F, Mitschke M, Aubin M, Xia P, Morin O, Bucci K, Roach M, Hernandez P, Zheng Z, Hristov D, Verhey L. PMID: 15736320.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimals
    230. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy. 2005; 4(3):202-6. Hsu IC, Cabrera AR, Weinberg V, Speight J, Gottschalk AR, Roach M, Shinohara K. PMID: 16182220.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    231. Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer. Oncology (Williston Park). 2005 Jan; 19(1):29-36; discussion 36, 39, 43-4. Andrews J, Roach M. PMID: 15743150.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    232. Is it time to change the standard of care from CT to MRI for defining the apex of the prostate to accomplish potency-sparing radiotherapy? Int J Radiat Oncol Biol Phys. 2005 Jan 01; 61(1):1-2. Roach M. PMID: 15629584.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    233. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1351-6. Roach M, Winter K, Michalski JM, Cox JD, Purdy JA, Bosch W, Lin X, Shipley WS. PMID: 15590164.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    234. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Nov 15; 60(4):1047-55. Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M. PMID: 15519774.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    235. Prostate movement during simulation resulting from retrograde urethrogram compared with "natural" prostate movement. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):470-5. Liu YM, Ling S, Langen KM, Shinohara K, Weinberg V, Pouliot J, Roach M. PMID: 15380581.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    236. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004 Nov; 233(2):441-8. Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J. PMID: 15375223.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    237. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1053-61. Zelefsky MJ, Moughan J, Owen J, Zietman AL, Roach M, Hanks GE. PMID: 15234039.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    238. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys. 2004 Jul 01; 59(3):665-73. Pickett B, Ten Haken RK, Kurhanewicz J, Qayyum A, Shinohara K, Fein B, Roach M. PMID: 15183469.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    239. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4118-24. Li R, Heydon K, Hammond ME, Grignon DJ, Roach M, Wolkov HB, Sandler HM, Shipley WU, Pollack A. PMID: 15217948.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    240. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 2004 Jun 01; 22(11):2133-40. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M, Shipley WU, Hanks GE, Sandler HM. PMID: 15169799.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    241. Treatment margins and prostate brachytherapy: "size matters," but how much and where? Cancer J. 2004 May-Jun; 10(3):158-9. Roach M. PMID: 15285924.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    242. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):6-10. Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M. PMID: 15093893.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    243. Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin North Am. 2004 May; 31(2):353-66. Roach M. PMID: 15123413.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    244. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):735-42. Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M, Sandler HM, Markoe AM, Cox JD. PMID: 14967428.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    245. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. PMID: 14752077.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    246. Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer. Rev Urol. 2004; 6 Suppl 8:S24-31. Roach M. PMID: 16985917; PMCID: PMC1472897.
      View in: PubMed   Mentions:
    247. Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol. 2003 Dec; 170(6 Pt 2):S35-40; discussion S40-1. Roach M. PMID: 14610408.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    248. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. PMID: 14610403.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    249. Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing". Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):907-9. Roach M. PMID: 14575819.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    250. A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Jul 15; 56(4):1073-8. Takamiya R, Weinberg V, Young CD, Sandler H, McLaughlin P, Roach M. PMID: 12829144.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    251. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):862-6. Pouliot J, Aubin M, Langen KM, Liu YM, Pickett B, Shinohara K, Roach M. PMID: 12788196.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    252. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):192-8. Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD. PMID: 12694838.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    253. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology. 2003 Apr; 61(4):730-5. Roach M, Weinberg V, McLaughlin PW, Grossfeld G, Sandler HM. PMID: 12670556.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    254. The evolving role of pelvic radiation therapy. Semin Radiat Oncol. 2003 Apr; 13(2):109-20. Roberts T, Roach M. PMID: 12728440.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    255. "Supplemental beam" and prostate brachytherapy: a simple answer to a complicated question? Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1162-3. Roach M. PMID: 12654420.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    256. Radiation medicine innovations for the new millenium. J Natl Med Assoc. 2003 Jan; 95(1):55-63. Heron DE, Godette KD, Wynn RA, Arterbery VE, Streeter OA, Roach M, Simpson JR, Blough M, Thomas CR. PMID: 12656450; PMCID: PMC2594374.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    257. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003 Jan; 169(1):245-50. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. PMID: 12478146.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    258. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002 Dec; 124(6):1183-9. Lee TT, Everett DL, Shu HK, Jahan TM, Roach M, Speight JL, Cameron RB, Phillips TL, Chan A, Jablons DM. PMID: 12447185.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    259. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1302-10. Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M. PMID: 12459350.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    260. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002 Nov 15; 54(4):1036-46. Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M, Sandler HM, Pollack A, Cox JD. PMID: 12419429.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    261. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):457-61. Lee WR, Roach M, Michalski J, Moran B, Beyer D. PMID: 12243822.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    262. Radical prostatectomy or external beam radiotherapy: one step forward or two steps back? Cancer. 2002 Jul 15; 95(2):215-8. Roach M. PMID: 12124818.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    263. The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):434-42. Pirzkall A, Carol MP, Pickett B, Xia P, Roach M, Verhey LJ. PMID: 12023148.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    264. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol. 2002 Jun; 29(3):264-73. Small EJ, Roach M. PMID: 12063679.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    265. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):75-80. Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach M, Parliament M, Pollack A, Markoe A, Harms WB, Sandler H, Cox JD. PMID: 11917289.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    266. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96(6):363-71. Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. PMID: 11745507.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    267. Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer. 2001 Jun 20; 96(3):198-209. Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, Montie J, Moul J, Pollack A, Raghavan D, Ray P, Roach M, Steinberg G, Stone N, Thompson I, Vogelzang N, Vijayakumar S. PMID: 11410889.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    268. Radiation Therapy Oncology Group. Research Plan 2002-2006. Outcomes Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):66-74. Watkins Bruner D, Berk L, Bondy M, Kachnic LA, Konski A, Layne E, Lee WR, Choucair A, Movsas B, Okunieff P, Roach M, Scott C, Vijayakumar S, Wenzel L, Radiation Therapy Oncology Group. PMID: 11641019.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    269. Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):28-38. Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, Hammond E, Hanks G, Heydon KH, Kaufman DS, Lee WR, Michalski J, Mydlo J, Pisansky T, Pollack A, Porterfield H, Rifkin M, Roach M, Sanda M, True L, Vijayakumar S, Winter KA, Zeitman A, Radiation Therapy Oncology Group. PMID: 11641012.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    270. NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park). 2000 Nov; 14(11A):111-9. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG, National Comprehensive Cancer Network. PMID: 11195405.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    271. Three-dimensional conformal external beam radiotherapy or brachytherapy: which is the "best alternative" to radical prostatectomy? CA Cancer J Clin. 2000 Nov-Dec; 50(6):344-7. Roach M. PMID: 11188755.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    272. Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology. 2000 Sep 01; 56(3):439-40. Roach M, Hsu I. PMID: 10962310.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    273. Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results. Am J Clin Oncol. 2000 Aug; 23(4):330-3. Wilder RB, Chou RH, Ryu JK, Stern RL, Wong MS, Ji M, Roach M, White RD. PMID: 10955856.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    274. Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1401-12. Pollack A, Paryani SB, Hussey D, Perez CA, Beyer DC, Blasko JC, Forman JD, Lee WR, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S. PMID: 11037555.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    275. Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1373-82. Forman JD, Lee WR, Roach M, Perez CA, Beyer DC, Blasko JC, Hussey DH, Paryani SB, Pollack A, Potters L, Scardino P, Schellhammer P, Leibel S. PMID: 11037553.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    276. Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1383-400. Potters L, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Roach M, Scardino P, Schellhammer P, Leibel S. PMID: 11037554.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    277. Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1413-8. Lee WR, Pollack A, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Paryani SB, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S. PMID: 11037556.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    278. Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1419-39. Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S. PMID: 11037557.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    279. Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun; 215 Suppl:1449-72. Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Potters L, Roach M, Scardino P, Schellhammer P, Leibel S. PMID: 11037559.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    280. Minimal toxicity with 3-FAT radiotherapy of prostate cancer. Semin Urol Oncol. 2000 May; 18(2):127-32. Weil MD, Crawford ED, Cornish P, Dzingle W, Stuhr K, Pickett B, Roach M. PMID: 10875453.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    281. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000 Jan 15; 46(2):391-402. Michalski JM, Purdy JA, Winter K, Roach M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD. PMID: 10661346.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    282. Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer? J Clin Oncol. 2000 Jan; 18(2):448-50. Roach M, Reese D, Weinberg V, Small EJ, Carroll PR. PMID: 10637263.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    283. Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01? Int J Radiat Oncol Biol Phys. 1999 Jul 15; 44(5):1047-52. Streeter OE, Martz KL, Gaspar LE, Delrowe JD, Asbell SO, Salter MM, Roach M. PMID: 10421537.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    284. Re: Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst. 1999 May 05; 91(9):801-3. Roach M, Forte D, Alexander M. PMID: 10328112.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    285. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys. 1999 May 01; 44(2):327-31. Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M, Andras EJ. PMID: 10760427.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    286. Management of locally advanced prostate cancer: new definitions and strategies. West J Med. 1998 Nov; 169(5):290-1. Roach M. PMID: 9830363; PMCID: PMC1305325.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    287. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998 Jul 01; 41(4):921-7. Bice WS, Prestidge BR, Grimm PD, Friedland JL, Feygelman V, Roach M, Prete JJ, Dubois DF, Blasko JC. PMID: 9652858.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    288. Sociodemographic analysis of patients in radiation therapy oncology group clinical trials. Int J Radiat Oncol Biol Phys. 1998 Jan 01; 40(1):9-15. Chamberlain RM, Winter KA, Vijayakumar S, Porter AT, Roach M, Streeter O, Cox JD, Bondy ML. PMID: 9422552.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    289. Localization of the prostatic apex for radiotherapy treatment planning using urethroscopy. Int J Radiat Oncol Biol Phys. 1997 Jul 01; 38(4):737-41. Wilder RB, Fone PD, Rademacher DE, Jones CD, Roach M, Earle JD, White RD. PMID: 9240640.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    290. Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities. Radiother Oncol. 1996 Jul; 40(1):85-7. Roach M. PMID: 8844893.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    291. Markers, CTs, urethrograms, and the prostatic apex. Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):207-9. Roach M, Holland J, Chan A, Shrieve D. PMID: 7995762.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    292. Calcium mass in human aortas from autopsy. Physiol Meas. 1994 Aug; 15(3):281-9. Sherebrin MH, Kim HL, Roach MR. PMID: 7994206.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    293. Participation in clinical trials: is it state-of-the-art treatment for African Americans and other people of color? J Natl Med Assoc. 1994 Mar; 86(3):177-82. Thomas CR, Pinto HA, Roach M, Vaughn CB. PMID: 8189450; PMCID: PMC2568186.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    294. Bilateral arcs using "averaged beam's eye views": a simplified technique for delivering 3-D based conformal radiotherapy. Med Dosim. 1994; 19(3):159-68. Roach M, Akazawa PF, Pickett B, Purser P, Parkinson D, Meyler TS, Margolis LW. PMID: 7818756.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    295. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. Lung Cancer. 1993 Dec; 10(3-4):189-97. Komaki R, Pajak TF, Byhardt RW, Emami B, Asbell SO, Roach M, Pedersen JE, Curran WJ, Lattin P, Russell AH, et al. PMID: 8075966.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    296. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993 Dec; 150(6):1923-4. Roach M. PMID: 7693984.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    297. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):493-8. Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M. PMID: 8226140.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    298. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys. 1993 Jul 15; 26(4):721-9. Vijayakumar S, Roach M, Wara W, Chan SK, Ewing C, Rubin S, Sutton H, Halpern H, Awan A, Houghton A, et al. PMID: 8331011.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    299. Factors in the initiation and propagation of aortic dissections in human autopsy aortas. J Biomech Eng. 1993 Feb; 115(1):123-5. Tiessen IM, Roach MR. PMID: 8445891.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    300. Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer. J Natl Cancer Inst. 1992 Nov 18; 84(22):1731-5. Graham MV, Geitz LM, Byhardt R, Asbell S, Roach M, Urtasun RC, Curran WJ, Lattin P, Russell AH, Cox JD. PMID: 1331484.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    301. The prognostic significance of race and survival from laryngeal carcinoma. J Natl Med Assoc. 1992 Aug; 84(8):668-74. Roach M, Alexander M, Coleman JL. PMID: 1507256; PMCID: PMC2571639.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    302. A digital-radiographic technique for in vitro tissue thickness measurement using iodine displacement. Med Phys. 1992 May-Jun; 19(3):545-54. Holdsworth DW, Dunmore PJ, Roach MR, Fenster A. PMID: 1508088.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    303. Race and survival from intracranial ependymomas in children. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1675-6. Roach M, Alexander M, Coleman JL. PMID: 1938578.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    304. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. Int J Radiat Oncol Biol Phys. 1991 May; 20(5):1047-52. Gandara DR, Valone FH, Perez EA, Deisseroth AB, Roach M, Ahn DK, Phillips T. PMID: 1850719.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    305. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol. 1990 Apr; 8(4):623-9. Roach M, Brophy N, Cox R, Varghese A, Hoppe RT. PMID: 2313331.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    Mack's Networks
    Concepts (442)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (87)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.